175 related articles for article (PubMed ID: 37182286)
21. Pipeline Therapies for Gout.
Yip K; Braverman G; Yue L; Fields T
Curr Rheumatol Rep; 2024 Mar; 26(3):69-80. PubMed ID: 38133712
[TBL] [Abstract][Full Text] [Related]
22. Gout.
Dalbeth N; Choi HK; Joosten LAB; Khanna PP; Matsuo H; Perez-Ruiz F; Stamp LK
Nat Rev Dis Primers; 2019 Sep; 5(1):69. PubMed ID: 31558729
[TBL] [Abstract][Full Text] [Related]
23. NLRP3 inflammasome inhibitor cucurbitacin B suppresses gout arthritis in mice.
Xue Y; Li R; Fang P; Ye ZQ; Zhao Y; Zhou Y; Zhang KQ; Li L
J Mol Endocrinol; 2021 Jun; 67(2):27-40. PubMed ID: 34047713
[TBL] [Abstract][Full Text] [Related]
24. Beneficial Properties of Phytochemicals on NLRP3 Inflammasome-Mediated Gout and Complication.
Jhang JJ; Lin JH; Yen GC
J Agric Food Chem; 2018 Jan; 66(4):765-772. PubMed ID: 29293001
[TBL] [Abstract][Full Text] [Related]
25. Enhancing the Response Rate to Recombinant Uricases in Patients with Gout.
Schlesinger N; Padnick-Silver L; LaMoreaux B
BioDrugs; 2022 Mar; 36(2):95-103. PubMed ID: 35316517
[TBL] [Abstract][Full Text] [Related]
26. Overview of hyperuricaemia and gout.
Masseoud D; Rott K; Liu-Bryan R; Agudelo C
Curr Pharm Des; 2005; 11(32):4117-24. PubMed ID: 16375732
[TBL] [Abstract][Full Text] [Related]
27. Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis.
Lee HE; Yang G; Park YB; Kang HC; Cho YY; Lee HS; Lee JY
Molecules; 2019 Jun; 24(11):. PubMed ID: 31174271
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
29. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis.
Joosten LA; Netea MG; Mylona E; Koenders MI; Malireddi RK; Oosting M; Stienstra R; van de Veerdonk FL; Stalenhoef AF; Giamarellos-Bourboulis EJ; Kanneganti TD; van der Meer JW
Arthritis Rheum; 2010 Nov; 62(11):3237-48. PubMed ID: 20662061
[TBL] [Abstract][Full Text] [Related]
30. Impact of pegloticase on patient outcomes in refractory gout: current perspectives.
Cunha RN; Aguiar R; Farinha F
Open Access Rheumatol; 2018; 10():141-149. PubMed ID: 30425593
[TBL] [Abstract][Full Text] [Related]
31. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
32. Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress.
Cao Y; Hu Y; Jin XF; Liu Y; Zou JM
Eur Rev Med Pharmacol Sci; 2023 Jan; 27(2):628-641. PubMed ID: 36734707
[TBL] [Abstract][Full Text] [Related]
33. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR; Saifer MG; Perez-Ruiz F
Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
[TBL] [Abstract][Full Text] [Related]
34. Andrographolide inhibits IL-1β release in bone marrow-derived macrophages and monocyte infiltration in mouse knee joints induced by monosodium urate.
Lo CW; Lii CK; Hong JJ; Chuang WT; Yang YC; Huang CS; Chen HW
Toxicol Appl Pharmacol; 2021 Jan; 410():115341. PubMed ID: 33242555
[TBL] [Abstract][Full Text] [Related]
35. Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation.
Yang G; Yeon SH; Lee HE; Kang HC; Cho YY; Lee HS; Lee JY
Rheumatology (Oxford); 2018 Apr; 57(4):727-736. PubMed ID: 29340626
[TBL] [Abstract][Full Text] [Related]
36. Polysaccharide extract from Isatidis Radix inhibits multiple inflammasomes activation and alleviate gouty arthritis.
Ren L; Li Q; Li H; Zhan X; Yang R; Li Z; Fang Z; Liu T; Wei Z; Zhao J; Lin L; Mou W; Dai W; Bai Z; Xu G; Cao J
Phytother Res; 2022 Aug; 36(8):3295-3312. PubMed ID: 35666808
[TBL] [Abstract][Full Text] [Related]
37. Tetrahydropalmatine attenuates MSU crystal-induced gouty arthritis by inhibiting ROS-mediated NLRP3 inflammasome activation.
Wang Y; Zhu W; Lu D; Zhang C; Wang Y
Int Immunopharmacol; 2021 Nov; 100():108107. PubMed ID: 34482265
[TBL] [Abstract][Full Text] [Related]
38. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin type 2 receptor antagonism as a new target to manage gout.
Vieira TN; Saraiva ALL; Guimarães RM; Luiz JPM; Pinto LG; de Melo Rodrigues Ávila V; Goulart LR; Cunha-Junior JP; McNaughton PA; Cunha TM; Ferreira J; Silva CR
Inflammopharmacology; 2022 Dec; 30(6):2399-2410. PubMed ID: 36173505
[TBL] [Abstract][Full Text] [Related]
40. Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression.
Cleophas MCP; Crişan TO; Klück V; Hoogerbrugge N; Netea-Maier RT; Dinarello CA; Netea MG; Joosten LAB
Arthritis Res Ther; 2019 Feb; 21(1):50. PubMed ID: 30728075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
